BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28652624)

  • 1. Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance.
    Lee SW; Kim JM; Lim HJ; Hwang YH; Kim SW; Chung W; Oh KH; Ahn C; Lee KB; Sung SA
    Sci Rep; 2017 Jun; 7(1):4260. PubMed ID: 28652624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
    Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
    Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepcidin and proinflammatory markers in children with chronic kidney disease: A case-control study
.
    Goyal KK; Saha A; Sahi PK; Kaur M; Dubey NK; Goyal P; Upadhayay AD
    Clin Nephrol; 2018 May; 89(5):363-370. PubMed ID: 29451472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Hepcidin and Iron Indices Affect Anemia Status Differently According to the Kidney Function of Non-Dialysis Chronic Kidney Disease Patients: Korean Cohort Study For Outcome in Patients with Chronic Kidney Disease (KNOW-CKD).
    Lee SW; Kim YH; Chung W; Park SK; Chae DW; Ahn C; Kim YS; Sung SA
    Kidney Blood Press Res; 2017; 42(6):1183-1192. PubMed ID: 29227972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.
    van der Weerd NC; Grooteman MP; Bots ML; van den Dorpel MA; den Hoedt CH; Mazairac AH; Nubé MJ; Penne EL; Gaillard CA; Wetzels JF; Wiegerinck ET; Swinkels DW; Blankestijn PJ; Ter Wee PM;
    PLoS One; 2012; 7(7):e39783. PubMed ID: 22808058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.
    Zaritsky J; Young B; Wang HJ; Westerman M; Olbina G; Nemeth E; Ganz T; Rivera S; Nissenson AR; Salusky IB
    Clin J Am Soc Nephrol; 2009 Jun; 4(6):1051-6. PubMed ID: 19406957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients.
    El Sewefy DA; Farweez BA; Behairy MA; Yassin NR
    Int Urol Nephrol; 2019 Feb; 51(2):325-334. PubMed ID: 30600440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance hemodialysis patients: results from a randomized controlled trial.
    Lim JH; Jeon Y; Yook JM; Choi SY; Jung HY; Choi JY; Park SH; Kim CD; Kim YL; Cho JH
    Sci Rep; 2020 Sep; 10(1):16062. PubMed ID: 32994531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients.
    Petrulienė K; Žiginskienė E; Kuzminskis V; Nedzelskienė I; Bumblytė IA
    Medicina (Kaunas); 2017; 53(2):90-100. PubMed ID: 28416170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats.
    Theurl M; Nairz M; Schroll A; Sonnweber T; Asshoff M; Haschka D; Seifert M; Willenbacher W; Wilflingseder D; Posch W; Murphy AT; Witcher DR; Theurl I; Weiss G
    Haematologica; 2014 Sep; 99(9):1516-24. PubMed ID: 24895335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of serum NGAL and hepcidin levels in chronic kidney disease patients.
    Avci Çiçek E; Rota S; Dursun B; Kavalci E
    Ren Fail; 2016; 38(1):35-9. PubMed ID: 26627016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum hepcidin levels are associated with serum triglycerides and interleukin-6 concentrations in patients with end-stage renal disease.
    Samouilidou E; Pantelias K; Petras D; Tsirpanlis G; Bakirtzi J; Chatzivasileiou G; Tzanatos H; Grapsa E
    Ther Apher Dial; 2014 Jun; 18(3):279-83. PubMed ID: 24119290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection].
    Milovanov YS; Mukhin NA; Kozlovskaya LV; Milovanova SY; Markina MM
    Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates.
    Troutt JS; Butterfield AM; Konrad RJ
    J Clin Lab Anal; 2013 Nov; 27(6):504-10. PubMed ID: 24218134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial.
    Atkinson MA; Juraschek SP; Bertenthal MS; Detrick B; Furth SL; Miller ER
    Pediatr Nephrol; 2017 May; 32(5):859-868. PubMed ID: 28013381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional erythropoietin-hepcidin axis in recombinant human erythropoietin independent haemodialysis patients.
    Touzot M; Lefebvre T; Roux A; Maheas C; Ridel C; Puy H; Karim Z
    Nephrology (Carlton); 2019 Jul; 24(7):751-757. PubMed ID: 30175513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease.
    Ueda N; Takasawa K
    Nutrients; 2018 Aug; 10(9):. PubMed ID: 30150549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study.
    Kakimoto-Shino M; Toya Y; Kuji T; Fujikawa T; Umemura S
    Ther Apher Dial; 2014 Oct; 18(5):421-6. PubMed ID: 24456328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients.
    Yılmaz I; Ozkok A; Kostek O; Kolukısa A; Duran I; Odabaş AR; Kemal Işman F; Işbilen Başok B
    Ren Fail; 2016; 38(1):89-95. PubMed ID: 26539647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients.
    Zaritsky J; Young B; Gales B; Wang HJ; Rastogi A; Westerman M; Nemeth E; Ganz T; Salusky IB
    Clin J Am Soc Nephrol; 2010 Jun; 5(6):1010-4. PubMed ID: 20299375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.